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Spheres of InfluenceThe biotechnology industry, however,
is adamant about making the distinction
between genes that appear in nature and
those that have been isolated, cloned, and
had their utility determined. Patent law is
clear, they point out, that while living mat-
ter is patentable, it must be living matter
that has been altered by humans for a utili-
tarian—and thus, patentable—purpose. A
gene itself, in other words, is not
patentable. And therefore, industry says,
people who are sounding the alarm about
“patenting human life” are simply wrong.
But critics contend that the U.S. Patent
and Trademark Office (PTO) has often
been overly liberal in its intepretation of
when these criteria are sufficient to reward
a patent. 
In December 1999, the PTO published
revised guidelines in the Federal Register
that would tighten the requirements neces-
sary for gene patents and issued a call for
comments. The office received scores of
responses, some perhaps predictable.
Industry responders cautioned against
tightening the requirements for patents too
much, while many scientists and medical
organizations supported a shift to looser
definitions of what may be patentable. One
of the scientists who responded was Barik,
who applauded the PTO’s strengthened
requirements for demonstrating utility. “If
you let greedy companies and their lawyers
patent naïve sequences, just imagine the
consequences,” he wrote. “Tomorrow,
Japan will sequence the whole rice genome,
China will sequence zebrafish, Bill Gates
will own Plasmodium, Donald Trump will
invest in the Sanger Centre and own 80%
of all coral reef anemones.” Although the
biotechnology industry contends that such
rhetoric is misinformed, the issue is still
hotly debated and, with the explosion of
activity in gene sequencing, will likely con-
tinue to be so. 
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Pending
Resolution:
The Question
of Who
Owns DNA
G
ene sequencing, says Sailen Barik, is no longer “rocket science.” Barik, an associate professor
of molecular biology at the University of South Alabama in Mobile, says that most of his
lab students are capable of finding genes—in fact, hundreds per student over a few months’
time—and sequencing them. “It is not difficult to do,” he says. “It does not require you to
go to a rain forest in Brazil. It’s not a natural product that’s hard to isolate or purify. Everyone has DNA
and genes. . . . You don’t have to invent anything new.” So why, he asks, should discovering genetic
sequences lead to patent protection for their finders? “The sole argument that ‘I did it first’ or ‘no one
has done it before’ does not make either the procedure or the result patentable,” he says.Patenting the Human Genome 
The biotechnology industry responds to
accusations like Barik’s with vigorous
denial. Nobody, they say, is trying to own
life forms. Still, the mapping of the
human genome opens huge potential
markets for pharmaceutical and biotech-
nologic product developments, which
take time and money. The question is,
how much patent protection should those
efforts enjoy?
The issue of gene patenting and its
relationship to restriction on research sur-
faced loudly in March when U.S. president
Bill Clinton and British prime minister
Tony Blair issued a joint statement urging
that genome information be made
freely available to the public. The
news sent many biotechnology
stocks tumbling and prompted J.
Craig Venter, president and chief
scientific officer of Celera Gen-
omics in Rockville, Maryland
(which has predicted that it will
have completed its mapping of the
human genome by the end of
2000), to state that the company
has never intended to keep other
scientists from using the informa-
tion it gathers. He said that Celera
would release the entire human
genome sequence when it was
completed, and would seek patents
on gene sequences for medically
important uses. 
The Clinton–Blair statement
also acknowledged the role that
patents play in providing an incen-
tive for research, stating that
“intellectual property protection
for gene-based inventions will also
play an important role in stimulat-
ing development of important new
health care products.” Clinton also
spoke up for gene patents at a press confer-
ence following the market downturn, say-
ing, “If someone discovers something that
has a specific commercial application, they
ought to be able to get a patent on it. And
the question is always going to be, are you
drawing the line in the right place?” 
Celera’s effort mirrors that of the pub-
licly financed Human Genome Project
(HGP), coordinated by the U.S. De-
partment of Energy and the National
Institutes of Health, which was created in
1990 for purposes of identifying all the
genes in human DNA by first determining
the sequence of some 3 billion nucleotides
that make up human DNA. To accom-
plish this, the two agencies, along with the
British Wellcome Trust, have funded
genome research projects in nearly 200
laboratories around the world. 
While private efforts are similar to
those of the HGP, they see genetic infor-
mation not as an end in itself, but as a
starting point for development of com-
pounds that may prove medically useful—
and profitable. In exchange for these
research investments, companies have
turned to the agency where private indus-
try always goes in hopes of securing finan-
cial protection for its efforts: the PTO.
Whom Do Patents Protect?
Ever since a landmark 1980 U.S.
Supreme Court ruling in Diamond v.
Chakrabarty, the patentability of some life
forms has existed. In that case, the court
found that a genetically engineered bac-
terium designed to “eat” oil (making it at
least theoretically useful in cleaning up
spills), invented by General Electric scien-
tist Ananda M. Chakrabarty, was
patentable because it was not found in
nature. The key to its decision, the court
stated, was that the organism was “made
by the hand of man.” In 1988, the “hand
of man” concept took its most dramatic
leap forward when the PTO granted a
patent to Harvard University researchers
for a genetically altered mouse used in
cancer research.
With the emergence of the HGP and
its private counterparts, the PTO began
receiving applications for gene-related
patents. While the limits of Chakrabarty
would seem to remove discovered genes
from patent protection, applicants have
been successful in getting patents for cer-
tain genetic information. The key measure
for applicants is in demonstrating ultimate
utility, according to Lila Feisee, intellectu-
al property counsel at the Biotechnology
Industry Organization, a trade group of
more than 900 members.
“When a gene is patented, it’s not the
gene that’s in your body,” she says.
“[Scientists] take DNA, they characterize
it, they identify what it does, how to use
it, so it’s not just something that’s in your
body. It’s been industrialized. It does have
the hand of man in it, and it is eligible for
patenting.” In addition, she says, a patent
is not ownership. A patent gives the paten-
tee the right to exclude others
from making, selling, or offering
to sell the invention for a limited
period of time in exchange for
full public disclosure.
One of the controversies that
has arisen in the new realm of
gene patenting, however, is that
patents have been granted for
mere gene fragments or partial
sequences known as expressed
sequence tags (ESTs), which are
devoid of much demonstrable
utility. “People make these ESTs,
they know a little about the gene,
but not much,” says Louis Myers,
an intellectual property lawyer
and biologist based in Boston,
Massachusetts, whose practice
regularly brings him to the PTO.
“They may know it’s expressed in
a certain kind of tissue, but they
don’t have the whole gene
sequence. They really don’t know
much about it. The question,
which has been hotly debated, is
this: If I have an EST, should I
be able to get a patent claim that
will later dominate the person who
[sequences] the whole gene, who finds out
what it does, what it’s useful for, and con-
tributes a lot of useful information? Or
should my patent claim be pretty strictly
limited to just the EST, which is not
tremendously useful?”
Myers says that, although there’s an
incentive for companies to seek patent
protection on relatively meager genetic
information, such patents can tie up subse-
quent research because it becomes costly
for researchers to pay multiple patent roy-
alty fees. “So you have to ask the question,
was that early contribution significant
enough that you’re willing to allow that
first person to dominate this downstream
activity?” he says.
By all accounts, the PTO is now mak-
ing it more difficult for applicants to
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If someone discovers 
something that has
a specific commercial application,
they ought to be able
to get a patent on it.
And the question is always
going to be, are you drawing
the line in the right place?
President Bill Clintonpatent genetic products. PTO spokes-
woman Brigid Quinn says that the move
to revise the guidelines was prompted by
two recent court decisions related to
patent utility. But some observers believe
that the PTO was under pressure from sci-
entists and groups concerned about the
ethics of patenting life forms.
“It had gotten so outrageous that they
were getting flak even from within the
industry,” says Jonathan King, a professor
of molecular biology at the Massachusetts
Institute of Technology in Cambridge.
“They’d started granting patents just on
fragments. That’s like saying, ‘I haven’t
figured out how to put the whole wind-
shield wiper together so it works,
but I’ve got the tip.’ There was
enough opposition to that within
the scientific community that they
were forced to make some gesture.”
King is also a board member of
an advocacy group called the
Council for Responsible Genetics,
which arose with the advent of
genetic engineering 25 years ago.
He’s been an outspoken opponent
of any kind of life-form patenting
since the days when the council
tried unsuccessfully to stimulate a
Congressional debate on the topic
in the wake of the narrow 5–4
Chakrabarty decision.
King contends that the
biotechnology industry is dodging
behind semantics when it argues
that genetic patents are not the
same thing as patents on life forms.
“Human gene sequences are not
inventions,” he says. “Sequences
are discovered, but they’re prod-
ucts of nature. When you discover
a new mineral you can’t patent it.
Just like the bottom of the ocean,
just like the atmosphere, just like the
moon are the common heritage of the
whole species, the genome is absolutely the
common inheritance of the entire species.
The notion that the human genome
should be private property is an egregious
form of theft of this common biological
heritage.”
The Effects of Gene Patenting on
Research
Critics of gene patenting contend that
one of its greatest dangers is that it retards
research. “Scientists generally are eager—
they can’t wait—to tell their colleagues
about their findings,” King says. “But in
patent law, if you publish a finding, it
becomes ‘prior art.’ So you cannot patent
a gene sequence once you’ve published it.
As a result, those people who are trying to
patent don’t talk. You go to a scientific
meeting, and you ask them a question,
and they’ll say, ‘I can’t answer that. There
are intellectual property rights issues.’
This whole rich culture of biomedical
research, this culture of cooperation and
communication, is now being strangled.”
By the time Clinton and Blair issued
their statement in March, troubling reports
regarding gene patents had made their way
into the news. A survey of U.S. laboratory
directors by the Stanford University Center
for Biomedical Ethics found that a quarter
of them had received letters from lawyers
representing biotechnology companies
ordering them to stop clinical tests for a
variety of disorders, including Alzheimer
disease and breast cancer. Because the clini-
cal tests that were stopped by legal threat
were those that patients pay for, the patent
holders were within their legal rights to
order stops to the tests. In December 1999,
the British newspaper The Guardian
reported that one such letter, from
Worcester, Massachusetts–based Athena
Diagnostics, informed recipients that the
company owned exclusive rights to certain
tests for the diagnosis of late-onset
Alzheimer disease under U.S. patent num-
ber 5,508,167—but that Athena would
perform the tests for $195 per specimen,
more than twice the standard rate being
charged by most university medical labs.
For many labs, the cost proved prohibitive.
There is no research exemption under
patent law, but in practice patents are not
enforced against researchers who use the
information for noncommercial purposes.
“There’s never been an instance where a
company has enforced a patent on some-
body who’s doing pure academic
research,” says Feisee. “In fact, it benefits
companies if other people are doing
research using their product. Now, the
minute that an academic researcher tries to
make money off it . . . then it becomes a
problem.”
Not surprisingly, the notion of gene
patenting has also spurred a backlash on
ethical grounds. In 1995, a coalition of
more than 80 religious groups held a press
conference denouncing all forms of gene
patenting. In August 1999, the
American College of Medical
Genetics issued a position paper
stating that genes are naturally
occurring substances that should
not be patented, and that licens-
ing agreements should not be
made prohibitive through exces-
sive royalties and other unrea-
sonable terms. In March 2000,
the Council for Responsible
Genetics responded to the
Clinton–Blair announcement by
issuing a statement calling for
the exclusion of human genes
from the patent system. 
“This is a question of nation-
al policy, not administrative pro-
cedure,” says King. “As a citizen,
I don’t care what patent lawyers
might think about it. This is my
DNA. These are my genes. I’m
not willing to leave it to the
Patent and Trademark Office to
decide the fate of the human
genome. I don’t think that’s
appropriate in a democracy.”
Regardless of the venue, the
controversy over gene patenting will con-
tinue to be played out. Whether gene
patenting will ultimately prevail in the
public’s consciousness, Myers says,
“depends on whether or not you believe
the patent system contributes to good for
people. It depends on whether or not you
think the patent system and its claims to
be able to attract money and investment
and capital and people into some areas to
solve problems speeds up or slows down
medical process. If you think it speeds it
up, then I think you should be in favor of
patenting genomic information. If you
think it slows it down, then you should be
against it.”
Richard Dahl
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Just like the bottom of the ocean,
just like the atmosphere,
just like the moon
are the common heritage
of the whole species,
the genome is absolutely
the common inheritance
of the entire species.
Jonathan King
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